Market Place
Sourcing Support
Immuneering Reports Survival Data in Pancreatic Cancer at ASCO
21 Apr 2026 //
GLOBENEWSWIRE
Immuneering`s AACR Data Backs Atebimetinib in Pancreatic Cancer
20 Apr 2026 //
GLOBENEWSWIRE
Immuneering Presents Atebimetinib Data at 2026 AACR Meeting
17 Mar 2026 //
GLOBENEWSWIRE
Immuneering To Present At Leerink Healthcare Conference
02 Mar 2026 //
GLOBENEWSWIRE
Immuneering Touts 64% Survival, Fueling Race With Revolution
08 Jan 2026 //
FIERCE BIOTECH
Immuneering Reports 64% 12-Month Survival in Pancreatic Cancer
07 Jan 2026 //
GLOBENEWSWIRE
Immuneering Announces 12-Month OS Data From Atebimetinib Trial
23 Dec 2025 //
GLOBENEWSWIRE
Immuneering Aligns with FDA, EMA on Atebimetinib Phase 3 Trial
17 Dec 2025 //
GLOBENEWSWIRE
Immuneering To Be Added To The Nasdaq Biotechnology Index (NBI)
16 Dec 2025 //
GLOBENEWSWIRE
Immuneering To Present At Piper Sandler Healthcare Conference
25 Nov 2025 //
GLOBENEWSWIRE
Immuneering Unveils Q3 2025 Financials & Business/Clinical Update
12 Nov 2025 //
GLOBENEWSWIRE
Immuneering To Present Q3 2025 Financials & New Clinical Cases
04 Nov 2025 //
GLOBENEWSWIRE
Immuneering To Share OS Data From Ph 2a Pancreatic Cancer Trial
26 Sep 2025 //
GLOBENEWSWIRE
Immuneering Boosts Pancreatic Cancer Survival By Nearly 2x
25 Sep 2025 //
BIOSPACE
Immuneering Appoints Dr. Thomas Schall as Board Chairman
16 Sep 2025 //
GLOBENEWSWIRE
Immuneering`s Ph 2a Update on Atebimetinib + mGnP for Cancer
10 Sep 2025 //
GLOBENEWSWIRE
Immuneering Announces Closing of $25 Million Private Placement
26 Aug 2025 //
GLOBENEWSWIRE
Immuneering Partners with Lilly for Atebimetinib-Olomorasib
25 Aug 2025 //
GLOBENEWSWIRE
Immuneering Secures $25M in Private Placement
21 Aug 2025 //
GLOBENEWSWIRE
Immuneering`s Q2 2025 Financial Results and Business Updates
13 Aug 2025 //
GLOBENEWSWIRE
Immuneering Sees 94% Survival at 6 Months in Pancreatic Cancer
17 Jun 2025 //
FIERCE BIOTECH
Immuneering to Update Phase 2a Trial of IMM-1-104 on June 17
16 Jun 2025 //
GLOBENEWSWIRE
Immuneering to Present at Jefferies Healthcare Conference
29 May 2025 //
GLOBENEWSWIRE
Immuneering Reports Q1 2025 Results and Business Updates
05 May 2025 //
GLOBENEWSWIRE
Immuneering to Present at Needham Healthcare Conference
02 Apr 2025 //
GLOBENEWSWIRE
Immuneering Reports Q4 Financial Results and Business Updates
20 Mar 2025 //
GLOBENEWSWIRE
Immuneering Announces Supply Agreement with Regeneron for IMM-1-104
06 Feb 2025 //
GLOBENEWSWIRE
Immuneering Shows Positive IMM-1-104 Data In Pancreatic Cancer
13 Jan 2025 //
GLOBENEWSWIRE
Immuneering Announces FDA Clearance of IND for Phase 1/2a Trial of IMM-6-415
12 Dec 2023 //
GLOBENEWSWIRE
Immuneering to Present Preclinical Data on IMM-1-104 and IMM-6-415
04 Oct 2023 //
GLOBENEWSWIRE
